Lack of BRAF activating mutations in prostate adenocarcinoma: A study of 93 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 121-125

  Liu, Ting ^a   Willmore Payne, Carlynn ^b   Layfield, Lester J ^a   Holden, Joseph A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

BRAF; High resolution DNA melting; Prostate carcinoma

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA DENATURATION; DNA ISOLATION; DNA SEQUENCE; GENE MUTATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEIC ACID DENATURATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 67849093853     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31818816b9     Document Type: Article

References (26)

1. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol. 2007;4:692-698. (Pubitemid 350187004)
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381.
3. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod. 2003;9:437-448.
4. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-599. (Pubitemid 47206938)
5. Saramaki O, Visakorpi T. Chromosomal aberrations in prostate cancer. Front Biosci. 2007;12:3287-3301.
6. Wang S, Garcia AJ, Wu M, et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA. 2006;103:1480-1485. (Pubitemid 43191191)
7. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 2007;67:6535-6538.
8. Moro L, Arbini AA, Yao JL, et al. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci. 2008;99:553-563. (Pubitemid 351228573)
9. Yang G, Timme TL, Frolov A, et al. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005;103:1186-1194. (Pubitemid 40328089)
10. Park JY, Zheng W, Kim D, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007;31:359-365. (Pubitemid 350166790)
11. Richter E, Masuda K, Cook C, et al. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007;2:100-109. (Pubitemid 351682003)
12. Parekh DJ, Ankerst DP, Baillargeon J, et al. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1966-1972. (Pubitemid 47621169)
13. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67:8504-8510. (Pubitemid 47437424)
14. Cho NY, Choi M, Kim BH, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006;119:1858-1862. (Pubitemid 44356843)
15. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17:31-39. (Pubitemid 46109299)
16. Lanzilotta SG, Grammatica L, Paradiso A, et al. BRAF in papillary thyroid carcinoma. Cell Oncol. 2007;29:269-277.
17. Benjamin CL, Melnikova VO, Ananthaswamy HN. Models and mechanisms in malignant melanoma. Mol Carcin. 2007;46:671-678.
18. Wan PT, Garnett MJ, Roe SM, et al. Cancer Genome Project. mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:764-766.
19. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocrine Relat Cancer. 2001;8:219-225. (Pubitemid 32947644)
20. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146-8151.
21. Willmore-Payne C, Holden JA, Hirschowitz S, et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol. 2006;37:520-527.
22. Holden JA, Willmore-Payne C, Coppola D, et al. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol. 2007;128:230-238. (Pubitemid 47262620)
23. Chou LS, Lyon E, Wittwer CT. A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning. Am J Clin Pathol. 2005;124:330-338.
24. Gundry CN, Vandersteen JG, Reed GH, et al. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem. 2003;49:396-406.
25. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med. 2006;354:526-528.
26. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232-7241. (Pubitemid 46095394)